5HT₆ receptor antagonists: a patent update. Part 1. Sulfonyl derivatives

Bibliography

• Monsma FJ, Shen Y, Ward RP, Cloning and expression of a novel serotonin receptor with high affinity for tricyclic psychotropic drugs. Mol Pharmacol 1993;43:320-7
   PubMed Web of Science ®Google Scholar
• Unsworth CD, Molinoff PB. Characterization of a 5–Hydroxytryptamine receptor in mouse neuroblastoma N18TG2 cells. J Pharmacol Exp Ther 1994;269:246-55
   PubMed Web of Science ®Google Scholar
• Kohen R, Metcalf MA, Khan N, Cloning, characterization, and chromosomal localization of a human 5HT6 serotonin receptor. J Neurochem 1996;66:47-56
   PubMed Web of Science ®Google Scholar
• Sebben M, Ansanay H, Bockaert J, Dumuis A. 5HT6 receptors positively coupled to adenylyl cyclase in striatal neurones in culture. Neuroreport 1994;5:2553-7
   PubMed Web of Science ®Google Scholar
• Roberts JC, Reavill C, East SZ, The distribution of 5HT(6) receptors in rat brain: an autoradiographic binding study using the radiolabelled 5HT(6) receptor antagonist [(125)I]SB-258585. Brain Res 2002;934:49-57
   PubMed Web of Science ®Google Scholar
• Gerard C, Mestikawy S, Lebrand C, Quantitative RT-PCR distribution of serotonin 5HT6 receptor mRNA in the central nervous system of control or 5,7-dihydroxytryptamine-treated rats. Synapse 1996;23:164-73
   PubMed Web of Science ®Google Scholar
• Dawson LA, Nguyen HQ, Li P. The 5HT(6) receptor antagonist SB-271046 selectively enhances excitatory neurotransmission in the rat frontal cortex and hippocampus. Neuropsychopharmacology 2001;25:662-8
   PubMed Web of Science ®Google Scholar
• Ivachtchenko AV, Ivanenkov YA, Tkachenko SE. 5HT6 receptor modulators: a patent survey. Expert Opin Ther Patents 2010;20:1247-57
   Web of Science ®Google Scholar
• Borsini EdF. Pharmacology of 5HT6 receptors; Part II, Intern. Rev Neurobiol Acad Press 2011;96:242
   Google Scholar
• Marazziti D, Baroni S, Dell'Osso MC, Serotonin receptors of type 6 (5HT6): what can we expect from them. Curr Med Chem 2011;18:2783-90
   PubMed Web of Science ®Google Scholar
• Marsden CA, King MV, Fone KC. Influence of social isolation in the rat on serotonergic function and memory-relevance to models of schizophrenia and the role of 5HT6 receptors. Neuropharmacology 2011;61:400-7
   PubMed Web of Science ®Google Scholar
• Codony X, Vela JM, Ramirez MJ. 5HT(6) receptor and cognition. Curr Opin Pharmacol 2011;11:94-100
   PubMed Web of Science ®Google Scholar
• Meneses A, Perez-Garcia G, Ponce-Lopez T, Castillo C. 5HT6 receptor memory and amnesia: behavioral pharmacology-learning and memory processes. Int Rev Neurobiol 2011;96:27-47
   PubMed Web of Science ®Google Scholar
• Borsini F, Bordi F, Riccioni T. 5HT6 pharmacology inconsistencies. Pharmacol Biochem Behav 2011;98:169-72
   PubMed Web of Science ®Google Scholar
• Borsini EDF. Pharmacology of 5HT6 receptors. Part I, Intern. Rev Neurobiol Acad Press 2010;95:2411
   Google Scholar
• Wesolowska A. Potential role of the 5HT6 receptor in depression and anxiety: an overview of preclinical data. Pharmacol Rep 2010;62:564-77
   PubMed Web of Science ®Google Scholar
• Fukuo Y, Kishi T, Yoshimura R, Serotonin 6 receptor gene and mood disorders: case-control study and meta-analysis. Neurosci Res 2010;67:250-5
   PubMed Web of Science ®Google Scholar
• Rosse G, Schaffhauser H. 5HT6 receptor antagonists as potential therapeutics for cognitive impairment. Curr Top Med Chem 2010;10:207-21
   PubMed Web of Science ®Google Scholar
• Glennon RA, Siripurapu U, Roth BL, The medicinal chemistry of 5HT6 receptor ligands with a focus on arylsulfonyltryptamine analogs. Curr Top Med Chem 2010;10:579-95
   PubMed Web of Science ®Google Scholar
• Liu KG, Robichaud AJ. 5HT6 antagonists as potential treatment for cognitive dysfunction. Drug Dev Res 2009;70:145-68
   Web of Science ®Google Scholar
• Geldenhuys WJ, Van der Schyf CJ. The serotonin 5HT6 receptor: a viable drug target for treating cognitive deficits in Alzheimer's disease. Expert Rev Neurother 2009;9:1073-85
   PubMed Web of Science ®Google Scholar
• Witty D, Ahmed M, Chuang TT. Advances in the design of 5HT6 receptor ligands with therapeutic potential. Prog Med Chem 2009;48:163-224
   PubMedGoogle Scholar
• Garfield AS, Heisler LK. Pharmacological targeting of the serotonergic system for the treatment of obesity. J Physiol 2009;587:49-60
   PubMed Web of Science ®Google Scholar
• King MV, Marsden CA, Fone KC. A role for the 5HT(1A), 5HT4 and 5HT6 receptors in learning and memory. Trends Pharmacol Sci 2008;29:482-92
   PubMed Web of Science ®Google Scholar
• Johnson CN, Ahmed M, Miller ND. 5HT6 receptor antagonists: prospects for the treatment of cognitive disorders including dementia. Curr Opin Drug Discov Devel 2008;11:642-54
   PubMedGoogle Scholar
• Geldenhuys WJ, Van der Schyf CJ. Serotonin 5HT6 receptor antagonists for the treatment of Alzheimer's disease. Curr Top Med Chem 2008;8:1035-408
   PubMed Web of Science ®Google Scholar
• Fone KC. An update on the role of the 5–Hydroxytryptamine6 receptor in cognitive function. Neuropharmacology 2008;55:1015-22
   PubMed Web of Science ®Google Scholar
• Upton N, Chuang TT, Hunter AJ, Virley DJ. 5HT6 receptor antagonists as novel cognitive enhancing agents for Alzheimer's disease. Neurotherapeutics 2008;5:458-69
   PubMed Web of Science ®Google Scholar
• Heal DJ, Smith SL, Fisas A, Selective 5HT6 receptor ligands: progress in the development of a novel pharmacological approach to the treatment of obesity and related metabolic disorders. Pharmacol Ther 2008;117:207-31
   PubMed Web of Science ®Google Scholar
• Halford JC, Harrold JA, Boyland EJ, Serotonergic drugs : effects on appetite expression and use for the treatment of obesity. Drugs 2007;67:27-55
   PubMed Web of Science ®Google Scholar
• Holenz J, Pauwels PJ, Diaz JL, Medicinal chemistry strategies to 5HT(6) receptor ligands as potential cognitive enhancers and antiobesity agents. Drug Discov Today 2006;11:283-99
   PubMed Web of Science ®Google Scholar
• Ramage AG. The role of central 5–Hydroxytryptamine (5HT, serotonin) receptors in the control of micturition. Br J Pharmacol 2006;147:120-31
   PubMed Web of Science ®Google Scholar
• Van der Schyf CJ, Geldenhuys WJ. Multimodal drugs and their future for Alzheimer's and Parkinson's disease. Int Rev 2011;100:107-5
   Web of Science ®Google Scholar
• Van der Schyf CJ. The use of multi-target drugs in the treatment of neurodegenerative diseases. Expert Rev Clin Pharmacol 2011;4:293-8
   PubMedGoogle Scholar
• Bang-Andersen B, Ruhland T, Jorgensen M, Discovery of 1-[2-(2,4-Dimethylphenylsulfanyl)phenyl]piperazine (Lu AA21004): a novel multimodal compound for the treatment of major depressive disorder. J Med Chem 2011;54:3206-21
   PubMed Web of Science ®Google Scholar
• Van der Schyf CJ, Geldenhuys WJ. Multimodal drugs and their future for Alzheimer's and Parkinson's disease. Int Rev c 2011;100:107-105
   Google Scholar
• Van der Schyf CJ. The use of multi-target drugs in the treatment of neurodegenerative diseases. Expert Rev Clin Pharmacol 2011;4:293-298
   PubMedGoogle Scholar
• Bang-Andersen B, Ruhland T, Jorgensen M, Smith G, Discovery of 1-[2-(2,4-Dimethylphenylsulfanyl)phenyl]piperazine (Lu AA21004): A Novel Multimodal Compound for the Treatment of Major Depressive Disorder. J Med Chem 2011;54:3206-3221
   PubMed Web of Science ®Google Scholar
• U.S. National Library of Medicine. Available from: www.pubmed.com
   Google Scholar
• Marazziti D, Baroni S, Catena Dell'Osso M, Serotonin receptors of type 6 (5HT6): what can we expect from them? Curr Med Chem 2011;18(18):2783-90
   PubMed Web of Science ®Google Scholar
• Heal D, Gosden J, Smith S. The 5HT6 receptor as a target for developing novel antiobesity drugs. Int Rev Neurobiol 2011;96:73-109
   PubMed Web of Science ®Google Scholar
• Di Chiara G, Valentini V, Fenu S. Behavioral and neurochemical pharmacology of 5HT6 receptors related to reward and reinforcement. Int Rev Neurobiol 2011;96:111-39
   PubMed Web of Science ®Google Scholar
• Borsini F, Bordi F, Riccioni T. 5HT6 pharmacology inconsistencies. Pharmacol Biochem Behav 2011;98(2):169-72
   PubMed Web of Science ®Google Scholar
• Liu KG, Robichaud AJ. 5HT6 medicinal chemistry. Int Rev Neurobiol 2010;94:1-34
   PubMed Web of Science ®Google Scholar
• Borsini F. Other 5HT6 receptor-mediated effects. Int Rev Neurobiol 2011;96:189-91
   PubMed Web of Science ®Google Scholar
• Mitchell ES. 5HT6 receptor ligands as antidementia drugs. Int Rev Neurobiol 2011;96:163-87
   PubMed Web of Science ®Google Scholar
• Arnt J, Olsen CK. 5HT6 receptor ligands and their antipsychotic potential. Int Rev Neurobiol 2011;96:141-61
   PubMed Web of Science ®Google Scholar
• Glennon RA, Siripurapu U, Roth BL, The medicinal chemistry of 5HT6 receptor ligands with a focus on arylsulfonyltryptamine analogs. Curr Top Med Chem 2010;10(5):579-95
   PubMed Web of Science ®Google Scholar
• Henderson AJ, Guzzo PR, Ghosh A, Epiminocyclohepta[b]indole analogs as 5HT6 antagonists. Bioorg Med Chem Lett 2012;22(4):1494-8
   PubMed Web of Science ®Google Scholar
• Nirogi R, Dwarampudi A, Kambhampati R, Bhatta V, Rigidized 1-aryl sulfonyl tryptamines: synthesis and pharmacological evaluation as 5HT6 receptor ligands. Bioorg Med Chem Lett 2011;21(15):4577-80
   PubMed Web of Science ®Google Scholar
• Nirogi R, Dwarampudi A, Kambhampati R, 5HT6 receptor ligands, EMD386088 and SB258585, differentially regulate 5HT6 receptor-independent events. Toxicol In Vitro 2011;25(8):2035-40
   PubMed Web of Science ®Google Scholar
• Da Silva Costa-Aze V, Quiedeville A, Boulouard M, Dauphin F. 5HT6 receptor blockade differentially affects scopolamine-induced deficits of working memory, recognition memory and aversive learning in mice. Psychopharmacology (Berl) 2012;222(1):99-115
   PubMed Web of Science ®Google Scholar
• Slassi A. Recent advances in 5HT1B/1D receptor antagonists and agonists and their potential therapeutic applications. Curr Top Med Chem 2002;2(6):559-74
   PubMedGoogle Scholar
• Unsworth CD, Molinoff PB. Characterization of a 5-hydroxytryptamine receptor in mouse neuroblastoma N18TG2 cells. J Pharmacol Exp Ther 1994;269(1):246-55
   PubMed Web of Science ®Google Scholar
• Holenz J, Merce R, Diaz JL, Medicinal chemistry driven approaches toward novel and selective serotonin 5HT6 receptor ligands. J Med Chem 2005;48(6):1781-95
   PubMed Web of Science ®Google Scholar
• Trani G, Baddeley SM, Briggs MA, Tricyclic azepine derivatives as selective brain penetrant 5HT6 receptor antagonists. Bioorg Med Chem Lett 2008;18(20):5698-700
   PubMed Web of Science ®Google Scholar
• Several databases including Prous Integrity Database. Available from: http://www.prous.com/integrity WIPO http://www.wipo.int Thomson Delphion http://www.delphion.com EPO http://www.epo.org; etc
   Google Scholar
• Suven Life Sciences Ltd, India. Аryl sulfonamide amine compounds and their use as 5HT6 ligands. WO032258; 2010
   Google Scholar
• Abbott Gmbh & Co. KG, Germany; Abbott Laboratories. N-phenyl-(piperazinyl or homopiperazinyl)-benzenesulfonamide or benzenesulfonyl-phenyl-(piperazine or homopiperazine) compounds suitable for treating disorders that respond to modulation of the serotonin 5HT6 receptor. WO125134; 2010
   Google Scholar
• Abbott GmbH & Co. KG, Germany. Benzenesulfonanilide compounds suitable for treating disorders that respond to modulation of the serotonin 5HT6 receptor. WO056632; 2009
   Google Scholar
• Abbott Gmbh & Co. KG, Germany; Abbott Laboratories. Benzenesulfonanilide compounds suitable for treating disorders that respond to modulation of the serotonin 5HT6 receptor. WO125135; 2010
   Google Scholar
• Abbott Gmbh & Co. KG, Germany; Abbott Laboratories. Benzenesulfonanilide compounds suitable for treating disorders that respond to modulation of the serotonin 5HT6 receptor. WO125136; 2011
   Google Scholar
• Laboratorios del Dr. Esteve, S. A, Spain. Naphthyl-substituted sulfonamides as 5HT6 receptor modulators. ES2344243B1; 2011
   Google Scholar
• Laboratorios del Dr. Esteve, S. A, Spain. 5HT6-Ligands such as sulfonamide derivatives in drug-induced weight-gain. ES2360164B1; 2012
   Google Scholar
• Korea Research Institute of Chemical Technology, S. Korea. Piperazine derivatives for preventing and treating central nervous system diseases. KR111508; 2010
   Google Scholar
• Laboratorios del Dr. Esteve, S. A, Spain. Substituted tetrahydro-quinoline-sulfonamide compounds, their preparation and use as medicament. US7964603B2; 2011
   Google Scholar
• Korea Research Institute of Chemical Technology, S. Korea. Preparation of piperazine-quinoline derivatives for prevention or treatment of central nervous system diseases. KR124020; 2010
   Google Scholar
• Laboratorios del Dr. Esteve, S. A, Spain. Substituted N-phenyl-2,3-dihydroimidazo[2,1-b]thiazole-5-sulfonamide derivatives as 5HT6 ligands. EP2116546; 2009
   Google Scholar
• Laboratorios del Dr. Esteve, S. A, Spain. Substituted N-phenyl-2,3-dihydroimidazo[2,1-b]thiazole-5-sulfonamide derivatives as 5HT6 ligands. WO135927; 2009
   Google Scholar
• Laboratorios del Dr. Esteve, S. A, Spain. N-Substituted imidazo[2,1-b]thiazole-5-sulfonamide derivatives as 5HT6 ligands. WO135925; 2009
   Google Scholar
• Laboratorios del Dr. Esteve, S. A, Spain. N-Substituted imidazo[2,1-b]thiazole-5-sulfonamide derivatives as 5HT6 ligands. EP2116547; 2009
   Google Scholar
• Laboratorios del Dr. Esteve, S. A, Spain. Combination of at least two 5HT6-Ligands. EP2020230; 2009
   Google Scholar
• Solvay Pharmaceuticals B. V, Netherlands. Arylsulfonyl pyrazoline carboxamidine derivatives as 5HT6 antagonists. WO115515; 2009
   Google Scholar
• Roche Palo Alto LLC, USA. Tetralin and indane derivatives as selective 5HT6 and 5HT2A receptor antagonists. US7671235; 2010
   Google Scholar
• Cephalon, Inc, USA. Tricyclic derivatives and their pharmaceutical serotonin receptors. WO087712; 2011
   Google Scholar
• Cephalon, Inc, USA. Tricyclic derivatives and their pharmaceutical use and compositions. WO087713; 2011
   Google Scholar
• Wyeth, John, and Brother Ltd. 1-Substituted-3-(naphthalen-1-ylsulfonyl)-5-(piperazin-1-yl)-1H-indazole compounds as 5-hydroxytryptamine-6 ligands. WO155399; 2009
   Google Scholar
• Suven Life Sciences Ltd. Substituted indolyl compounds and their use as 5HT6 ligands. WO034581; 2009
   Google Scholar
• Suven Life Sciences Ltd. Aminoarylsulfonamide compounds and their use as 5HT6 ligands. WO053997; 2009
   Google Scholar
• Suven Life Sciences Ltd. Aminoarylsulfonamide compounds and their use as 5HT6 ligands. EP2200980; 2010
   Google Scholar
• Suven Life Sciences Ltd. Novel sulfone compounds as 5HT6 receptor ligands. INCH00018; 2011
   Google Scholar
• Suven Life Sciences Ltd, India. Arylindolyl sulfonamide compounds and their use as 5HT6 ligands. WO032257; 2010
   Google Scholar
• Merck & Co, Inc. Tryptaminesulfonamides as serotonin 5HT6 antagonists. WO073118; 2009
   Google Scholar
• Laboratorios del Dr. Esteve, S.A. Substituted indole sulfonamide compounds, their preparation and use as medicaments. WO012806; 2010
   Google Scholar
• Laboratorios del. Dr. Esteve, S.A. Substituted indole sulfonamide compounds their preparation and use as medicaments. EP2149573; 2010
   Google Scholar
• Memory Pharmaceuticals Corp. 3-Substituted compounds having 5HT6 receptor affinity. WO023844; 2009
   Google Scholar
• Memory Pharmaceuticals Corp. 4'-Amino cyclic compounds having 5HT6 receptor affinity. WO024980; 2010
   Google Scholar
• Memory Pharmaceuticals Corp. 4'-Amino cyclic compounds having 5HT6 receptor affinity. US0056491; 2010
   Google Scholar
• Memory Pharmaceuticals Corp. Pyrrolo-pyridine-3-yl piperazine derivatives having 5HT6 receptor affinity. WO008832; 2010
   Google Scholar
• Memory Pharmaceuticals Corp. Pyrrolo-pyridine-3-yl piperazine derivatives having 5HT6 receptor affinity. US0016297; 2010
   Google Scholar
• Memory Pharmaceuticals Corp. Condensed heterocyclic compounds having 5HT6 receptor affinity. WO021797; 2010
   Google Scholar
• Memory Pharmaceuticals Corp. Pyrrolidine-substituted azaindole compounds having 5HT6 receptor affinity. WO002802; 2010
   Google Scholar
• Memory Pharmaceuticals Corp. Pyrrolidine-substituted azaindole compounds having 5HT6 receptor affinity. US0022581; 2010
   Google Scholar
• Memory Pharmaceuticals Corp. Acyclic compounds having 5HT6 receptor affinity. WO011546; 2010
   Google Scholar
• Memory Pharmaceuticals Corp. Acyclic compounds having 5HT6 receptor affinity. US0029629; 2010
   Google Scholar
• Wyeth, John, and Brother Ltd. 1-(Arylsulfonyl)-4-(piperazin-1-yl)-1H-benzimidazole as 5-hydroxytryptamine-6 ligands. US0120779; 2010
   Google Scholar
• H. Lundbeck A/S. Novel 4-(aryl-4-sulfonyl)-6,6a,7,8,9,10-hexahydro-4H-4,8,10a-triazaacephenanthrylene and 3-arylsulfonyl-6,6a,7,8,9,10-hexahydro-3H-3,8,10a-triazacyclo-penta[c]fluorene derivatives as serotonin 5HT6 ligands. WO088836; 2011
   Google Scholar
• Ivachtchenko AA, Savchuk NP, Ivachtchenko AV. 3-Sulfonyl-pyrazolo[1,5-a]pyrimidines, antagonists of serotonin 5HT6 receptors, methods for the production and use thereof. WO093206; 2009
   Google Scholar
• Ivachtchenko AV, Savchuk NP, Ivachtchenko AA. Substituted 4-sulfonyl-pyrazoles and 3-sulfonyl-pyrazolo[1,5-a]pyrimidines, antagonists of serotonin 5HT6 receptors, active component, pharmaceutical composition, drag and methods for the production. RU2369600; 2009
   Google Scholar
• Ivachtchenko AA, Ivachtchenko AV, Savchuk NP. Substituted 2-amino-3-sulfonyl-pyrazolo[1,5-a]pyrimidines, antagonists of serotonin 5HT6 receptors, methods for the production and use thereof. WO093208; 2009
   Google Scholar
• Ivachtchenko AV, Savchuk NP, Ivachtchenko AA. Substituted 3,5-diamino-4-sulfonyl-pyrazoles and 2-amino-3-sulfonyl-pyrazolo[1,5-a]pyrimidines, antagonists of serotonin 5HT6 receptors, methods for the production and use thereof. RU2376291; 2009
   Google Scholar
• Ivachtchenko AA, Ivachtchenko AV, Savchuk NP. Substituted 2-alkylsulfanyl-3-sulfonyl-cycloalkano[e or d]pyrazolo[1,5-a]pyrimidines, antagonists of serotonin 5HT6 receptors, methods for the production and use thereof. WO093209; 2009
   Google Scholar
• Ivachtchenko AV, Savchuk NP, Ivachtchenko AA. 2-alkylamino-3-sulfonyl-cycloalkano[e or d]pyrazolo[1,5-a]pyrimidines, antagonists of serotonin 5HT6 receptors, methods for the production and use thereof. RU2377244; 2009
   Google Scholar
• Ivachtchenko AA, Ivachtchenko AV, Savchuk NP. Substituted cycloalkano[e or d]pyrazolo[1,5-a]pyrimidines, antagonists of serotonin 5HT6 receptors, methods for the production and use thereof. WO093210; 2009
   Google Scholar
• Ivachtchenko AV, Savchuk NP, Ivachtchenko AA. Substituted cycloalkano[e or d]pyrazolo[1,5-a]pyrimidines, antagonists of serotonin 5HT6 receptors, methods for the production and use thereof. RU2374249; 2009
   Google Scholar
• Ivachtchenko AA, Kysil VM, Savchuk NP, Ivachtchenko AV. 2-Aamino-3-sulfonyl-pyrazolo[1,5-a]pyrimidines, antagonists of serotonin 5HT6 receptors, methods for the production and use thereof. WO136813; 2009
   Google Scholar
• Ivachtchenko AV, Ivachtchenko AA, Savchuk, NP, Kysil VM. Substituted 2-amino-3-sulfonyl-pyrazolo[1,5-a]pyrimidines, antagonists of serotonin 5HT6 receptors, methods for the production and use thereof. RU2384581; 2010
   Google Scholar
• Ivachtchenko AV, Kysil VM, Ivachtchenko AA, Savchuk NP. Tetrahydro-pyrazolo[1,5-a]pyrido-pyrimidines as antagonists of serotonin 5HT6 receptors, methods for the production and use thereof. RU239134; 2010
   Google Scholar
• Ivachtchenko AA, Ivachtchenko AV, Savchuk NP, Substituted 3-arylsulfonyl-cycloalkano[e or d]pyrazolo[1,5-a]pyrimidines, antagonists of serotonin 5HT6 receptors, methods for the production and use thereof. WO041983; 2010
   Google Scholar
• Ivachtchenko AV, Savchuk NP, Ivachtchenko AA. 3-Alkylamino-3-arylsulfonyl-pyrazolo[1,5-a]pyrimidines, antagonists of serotonin 5HT6 receptors, methods for the production and use thereof. RU2393157; 2010
   Google Scholar
• Ivachtchenko AV, Savchuk NP, Ivachtchenko AA. Substituted 3-arylsulfonyl-pyrazolo[1,5-a]pyrimidines, antagonists of serotonin 5HT6 receptors, methods for the production and use thereof. RU2393158; 2010
   Google Scholar
• Ivachtchenko AV, Savchuk NP, Ivachtchenko AA. Substituted 2-alkylsulfanyl-3-sulfonyl-pyrazolo[1,5-a]pyrimidines, antagonists of serotonin 5HT6 receptors, methods for the production and use thereof. RU2393159; 2010
   Google Scholar
• Ivachtchenko AV, Savchuk NP, Ivachtchenko AA. Substituted 2-alkylamino-3-sulfonyl-pyrazolo[1,5-a]pyrimidines, antagonists of serotonin 5HT6 receptors, methods for the production and use thereof. RU2399621; 2010
   Google Scholar
• Bayer Pharmaceuticals Corp. 4-Sulfide/sulfoxide/sulfonyl-1h-pyrazolyl derivative compounds, for use in diseases associated with the 5HT2C receptor. WOA12003057674; 2003
   Google Scholar
• Hoffmann La Roche. Pyrazolopyrimidines and pyrazolotriazines with 5HT6 receptor affinity. EPA1941994; 1999
   Google Scholar
• Alla Chem, LLC. 3-Sulfonyl-pyrazolo[1,5-a]pyrimidines as antagonists of serotonin 5HT6 receptors and methods for their production and use thereof. WO093206; 2009
   Google Scholar
• Alla Chem, LLC. Substituted 4-sulfonylpyrazoles and 3-sulfonylpyrazolo[1,5-a]pyrimidines – antagonists of serotonin 5HT6 receptors, active component, pharmaceutical composition, medicinal agent and method of obtaining them. RU2369600; 2009
   Google Scholar
• Alla Chem, LLC. 3-Sulfonyl-pyrazolo[1,5-a]pyrimidines as antagonists of serotonin 5HT6 receptors and methods for their production and use thereof. US331347; 2010
   Google Scholar
• Alla Chem, LLC. 2-Alkylamino-3-arylsulfonyl-cycloalkano [e or d] pyrazolo[1,5-a]pyrimidines/ antagonists of serotonin 5HT6 receptors methods for the production and the use in thereof. WO093209; 2009
   Google Scholar
• Alla Chem, LLC. Substituted cycloalkano[e and d]pyrazolo[1,5-a]pyrimidines/antagonists of serotonin 5HT6 receptors and methods for their production and use thereof. WO093210; 2009
   Google Scholar
• Ivachtchenko AV, Golovina ES, Kadieva MG, The antagonists of serotonin 5HT6 receptors. Substituted 3-benzenesulfonyl-pyrazolo[1,5-a]pyrido[4,3-e]pyrimidines and 3-benzenesulfonyl-pyrazolo[1,5-a]pyrido[4,3-d]pyrimidines - synthesis and “Structure-Activity” relationship. J Med Chem 2012. [in press]
   Google Scholar
• Alla Chem, LLC. Substituted 2-amino-3-(arylsulfonyl)pyrazolo[1,5-a]pyrimidines as antagonists of serotonin 5HT6 receptors, methods for the production and thereof. WO093208; 2009
   Google Scholar
• Alla Chem, LLC. Substituted 3-arylsulfonylpyrazolo[1,5-a]pyrimidines, serotonin 5HT6 receptors antagonists, and methods for the production and their use thereof. WO041983; 2010
   Google Scholar
• Alla Chem, LLC. Substituted 2-(alkylamino)-3-(arylsulfonyl)pyrazolo[1,5-a]pyrimidines serotonin 5HT6 receptors antagonists, and methods for the production and their use thereof. RU2393157; 2010
   Google Scholar
• Alla Chem, LLC. Substituted 3-(arylsulfonyl)pyrazolo[1,5-a]pyrimidines as antagonists of serotonin 5HT6 receptors, and methods for the production and their use thereof. RU2393158; 2010
   Google Scholar
• Alla Chem, LLC. Tetrahydropyrazolo[1,5-a]pyrido-pyrimidines as antagonists of serotonin 5HT6 receptors, methods for their production and use thereof. WO136814; 2009
   Google Scholar
• Alla Chem, LLC. 2-Amino-3-sulfonyl-6,7,8,9-tetrahydropyrazolo[1,5-a]pyrido[4,3-e]pyrimidines – antagonists serotonin 5HT6, methods for the production and use thereof. WO136813; 2009
   Google Scholar
• Alla Chem, LLC. Substituted 2-amino-3-sulfonyl-6,7,8,9-tetrahydropyrazolo[1,5-a]pyrido[4,3-e]pyrimidines - serotonin 5HT6 receptor antagonists and methods for the production and their use thereof. RU2384581; 2010
   Google Scholar
• Ivachtchenko AV, Golovina ES, Kadieva MG, 2-Substituted 5,6-dimethyl-3-phenylsulfonyl-pyrazolo[1,5-a]pyrimidines: new series of highly potent and specific serotonin 5-HT6 receptor antagonists. Eur J Med Chem 2011;46(4):1189-97
   PubMed Web of Science ®Google Scholar
• Alla Chem, LLC. Substituted 3-sulfonyl[1,2,3]triazolo[1,5-a]pyrimidines – antagonists of serotonin 5HT6 receptors, medicinal substance, pharmaceutical compositions, medicinal preparation and methods for the production thereof. WO093934; 2009
   Google Scholar
• Ivachtchenko AV, Golovina ES, Kadieva MG, Synthesis and biological study of 3-(phenylsulfonyl)thieno[2,3-e][1,2,3]triazolo[1,5-a]pyrimidines as potent and selective serotonin 5HT6 receptor antagonists. Bioorg Med Chem 2010;18(14):5282-90
   PubMed Web of Science ®Google Scholar
• Kost AN, Vinogradova EV, Daut Kh, . Alkaloids and alkaloid-like structures. Khim 1962;32:2050
   Google Scholar
• Hung D. Hydrogenated pyrido[4,3-b]indoles such as Dimebon for treating canine cognitive dysfunction syndrome. WO036400; 2008. [Chem. Abstr. 2008, 148, 369989]
   Google Scholar
• Grigorev VV, Dranyi OA, Bachurin SO. Comparative study of action mechanisms of dimebon and memantine on AMPA- and NMDA-subtypes glutamate receptors in rat cerebral neurons Bull Exp Biol Med 2003;136:474
   PubMed Web of Science ®Google Scholar
• Lermontova NN, Lukoyanov NV, Serkova TP, Dimebon improves learning in animals with experimental Alzheimer's disease Bull Exp Biol Med 2000;129:544
   PubMed Web of Science ®Google Scholar
• Bachurin SO, Shevtsova EP, Kireeva EG, Mitochondria as a target for neurotoxins and neuroprotective agents Ann NY Acad Sci 2003;993:334
   PubMed Web of Science ®Google Scholar
• Lermontova NN, Redkozubov AE, Shevtsova EF, Dimebon and tacrine inhibit neurotoxic action of beta-amyloid in culture and block L-type Ca2+ channels Bull Exp Biol Med 2001;132:1079
   PubMed Web of Science ®Google Scholar
• Hung D. Dimebon, 11th Int. Conf. Alzheimer's Dis. Relat. Disord. (ICAD); 26 – 31 July 2008; Chicago
   Google Scholar
• Tkachenko SE, Ivachtchenko AV, Khvat A, 1st International Conference on Drug Design and Discovery; 2 – 6 February 2008; Dubai
   Google Scholar
• Tkachenko SE, Ivachtchenko AV, Khvat A, 11th Int. Conf. Alzheimer's Dis. Relat. Disord. (ICAD); 26-31 July 2008; Chicago
   Google Scholar
• Tkachenko SE, Khvat A, Lavrovsky Y, XXth International Symposium on Medicinal Chemistry
   Google Scholar
• Lavrovsky Y, Ivachtchenko A, Morozova M, Preclinical and early clinical studies of AVN-101, a novel balanced molecule for the treatment of Alzheimer's disease. Alzheimer's Association International Conference on Alzheimer's Disease; 2010. p. 3-442
   Google Scholar
• Ivashchenko AV, Lavrovsky Y, Mitkin O, Discovery and Preclinical Studies of AVN-101, a Novel “Balanced” Molecule for Treatment of Alzheimer Disease (AD)
   Google Scholar
• Dimebon Disappoints in Phase 3 Trial of Huntington's Disease. Medscape. Available from: http://www.medscape.com/viewarticle/740692 [Last accessed 12 April 2011]
   Google Scholar
• Medivation, Pfizer End Work on Alzheimer's Drug. WSJ Blogs. Available from: http://online.wsj.com/article/SB10001424052970204555904577166522162859292.html [Last accessed 18 January 2012]
   Google Scholar
• A.M. Vitals: Pfizer, Medivation End Dimebon Development. WSJ Blogs. Available from: http://blogs.wsj.com/health/2012/01/18/a-m-vitals-pfizer-medivation-end-dimebon-development/ [Last accessed 18 January 2012]
   Google Scholar
• Ivachtchenko AV, Kisil' VM, Mit'kin OD, Substituted 8-sulfonyl-2,3,4,5-tetrahydro-1h-gamma-carbolines, ligands and pharmaceutical composition; method for the production and use of same. RU2404180; 2010
   Google Scholar
• Alla Chem, LLC. Substituted 8-sulfonyl-2,3,4,5-tetrahydro-1H-gamma-carbolines, ligands and pharmaceutical composition; method for their production and use of same. WO134846; 2010
   Google Scholar
• Alla Chem, LLC. Substituted 8-sulfonyl-2,3,4,5-tetrahydro-1H-gamma-carbolines as ligands towards a wide range of receptors, and their preparation and use in the treatment and prophylaxis of CNS diseases. RU2404180; 2010
   Google Scholar
• Alla Chem, LLC. Substituted 8-sulfonyl-2,3,4,5-tetrahydro-1H-gamma-carbolines, ligands and pharmaceutical composition; method for their production and use of same. WO134846; 2010
   Google Scholar
• Alla Chem, LLC. Substituted 8-sulfonyl-2,3,4,5-tetrahydro-1H-gamma-carbolines as ligands towards a wide range of receptors, and their preparation and use in the treatment and prophylaxis of CNS diseases. RU2404180; 2010
   Google Scholar
• Kohen R, Fashingbauer LA, Heidmann DE, Cloning of the mouse 5HT6 serotonin receptor and mutagenesis studies of the third cytoplasmic loop. Brain Res Mol Brain Res 2001;90:110-17
   PubMedGoogle Scholar
• Teitler M, Herrick-Davis K, Purohit A. Constitutive activity of G-protein coupled receptors: emphasis on serotonin receptors. Curr Top Med Chem 2002;2:529-38
   PubMedGoogle Scholar
• Romero G, Sanchez E, Pujol M, Efficacy of selective 5HT6 receptor ligands determined by monitoring 5HT6 receptor-mediated cAMP signaling pathways. Br J Pharmacol 2006;148:1133-43
   PubMed Web of Science ®Google Scholar
• Riemer C, Borroni E, Levet-Trat B, Influence of the 5HT6 receptor on acetylcholine release in the cortex: pharmacological characterization of 4-(2-bromo-6-pyrrolidin-1-ylpyridine-4-sulfonyl)phenylamine, a potent and selective 5HT6 receptor antagonist. Med Chem 2003;46:1273-6
   Web of Science ®Google Scholar
• Meneses A. Role of 5HT6 receptors in memory formation. Drug News Perspect 2001;14:396-400
   PubMed Web of Science ®Google Scholar
• Hirst WD, Stean TO, Rogers DC, SB-399885 is a potent, selective 5HT6 receptor antagonist with cognitive enhancing properties in aged rat water maze and novel object recognition models. Eur J Pharmacol 2006;553:109-19
   PubMed Web of Science ®Google Scholar
• Lieben CK, Blokland A, Sik A, The selective 5HT6 receptor antagonist Ro4368554 restores memory performance in cholinergic and serotonergic models of memory deficiency in the rat. Neuropsychopharmacology 2005;30:2169-79
   PubMed Web of Science ®Google Scholar
• Marcos B, Gil-Bea FJ, Hirst WD, Lack of localization of 5HT6 receptors on cholinergic neurons: implication of multiple neurotransmitter systems in 5HT6 receptor-mediated acetylcholine release. Eur J Neurosci 2006;24:1299-306
   PubMed Web of Science ®Google Scholar
• Dawson LA, Nguyen HQ, Li P. In vivo effects of the 5HT(6) antagonist SB-271046 on striatal and frontal cortex extracellular concentrations of noradrenaline, dopamine, 5HT, glutamate and aspartate. Br J Pharmacol 2000;130:23-6
   PubMed Web of Science ®Google Scholar
• Schechter LE, Lin Q, Smith DL, Neuropharmacological profile of novel and selective 5HT6 receptor agonists: WAY-181187 and WAY-208466. Neuropsychopharmacology 2008;33:1323-35
   PubMed Web of Science ®Google Scholar
• Mitchell ES, Neumaier JF. 5HT6 receptors: a novel target for cognitive enhancement. Pharmacol Ther 2005;108:320-33
   PubMed Web of Science ®Google Scholar
• Ballaz SJ, Akil H, Watson SJ. Analysis of 5HT6 and 5HT7 receptor gene expression in rats showing differences in novelty-seeking behavior. Neuroscience 2007;147:428-38
   PubMed Web of Science ®Google Scholar
• Svenningsson P, Tzavara ET, Qi H, Biochemical and behavioral evidence for antidepressant-like effects of 5HT6 receptor stimulation. Neuroscience 2007;27:4201-9
   PubMed Web of Science ®Google Scholar
• Wesolowska A, Nikiforuk A. Effects of the brain-penetrant and selective 5HT6 receptor antagonist SB-399885 in animal models of anxiety and depression. Neuropharmacology 2007;52:1274-83
   PubMed Web of Science ®Google Scholar
• Fisas A, Codony X, Romero G, Chronic 5HT6 receptor modulation by E-6837 induces hypophagia and sustained weight loss in diet-induced obese rats. Br J Pharmacol 2006;148:973-83
   PubMed Web of Science ®Google Scholar
• De Foubert G, O'Neill MJ, Zetterstrom TS. Acute onset by 5HT6-receptor activation on rat brain-derived neurotrophic factor and activity-regulated cytoskeletal-associated protein mRNA expression. Neuroscience 2007;147:778-85
   PubMed Web of Science ®Google Scholar
• Cole DC, Stock JR, Lennox WJ, Discovery of N1-(6-chloroimidazo[2,1-b][1,3]-thiazole-5-sulfonyl)tryptamine as a potent, selective, and orally active 5HT6 receptor agonist. J Med Chem 2007;50:5535-8
   PubMed Web of Science ®Google Scholar
• Ivachtchenko AV, Golovina EV, Kadieva MD, Synthesis and Structure 5–HТ6 receptor antagonistic activity relationship of substituted bis-phenylsulfones. Chem Biol Drug Des 2012;80(3): [in press]
   Google Scholar
• Ivachtchenko AV, Kadieva MD, Mitkin OD. Synthesis and pharmacological activity of methyl-(3-piperazin-1-yl-6-fenylsulfonylfenyl)-amine [abstracts]. In Second Scientific Conference with international participation “The successes and the synthesis of complex” on the 95th anniversary of the birth of Professor N. Prostakov, Peoples' Friendship University of Russia (RUDN); 23 – 27 April 2012; Moscow, Russia
   Google Scholar
• Ivachtchenko AV, Kadieva MD, Mitkin OD. Substituted methyl-amines, antagonists, serotonin 5HT6 receptor, methods for the production and use thereof. RU152052; 2010
   Google Scholar
• Ivachtchenko AV, Kadieva MD, Mitkin OD. Synthesis and pharmacological activity of methyl-(8-piperazin-1-yl)-3-phenylsulfonyl-quinolin-4-yl)-amine [abstracts]. In Organic Synthesis: Chemistry and Technology. The Ural Federal University; 4 – 8 June 2012; Russia, Ekaterinburg
   Google Scholar
• Harris RN III, Stabler RS, Repke DB, Highly potent, non-basic 5HT6 ligands. Site mutagenesis evidence for a second binding mode at 5HT6 for antagonism. Bioorg Med Chem Lett 2010;20:3436-40
   PubMed Web of Science ®Google Scholar